Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
Gianni Bisogno, MD, of the University Hospital of Padova, discusses study findings on maintenance low-dose chemotherapy in patients with high-risk rhabdomyosarcoma (Abstract LBA2).
Nathan A. Pennell, MD, PhD, of the Cleveland Clinic, discusses the economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in newly diagnosed metastatic non–small cell lung cancer (Abstract 9031).
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses phase II study findings on the addition of durvalumab to a taxane-anthracycline–containing chemotherapy in triple-negative breast cancer (Abstract 104).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.
Aviva C. Krauss, MD, of the U.S. Food and Drug Administration, discusses findings on an FDA analysis of immune-related adverse events and response to pembrolizumab in multiple myeloma (Abstract 8008).
